Abstract
There is growing concern about the poor quality and lack of repeatability of many pre-clinical experiments involving laboratory animals. According to one estimate as much as $28 billion is wasted annually in the USA alone in such studies. A decade ago the FDA’s “Critical path” white paper noted that “The traditional tools used to assess product safety—animal toxicology and outcomes from human studies—have changed little over many decades and have largely not benefited from recent gains in scientific knowledge. The inability to better assess and predict product safety leads to failures during clinical development and, occasionally, after marketing.” Repeat-dose 28-days and 90-days toxicity tests in rodents have been widely used as part of a strategy to assess the safety of drugs and chemicals but their repeatability and power to detect adverse effects have not been formally evaluated.
The guidelines (OECD TG 407 and 408) for these tests specify the dose levels and number of animals per dose but do not specify the strain of animals which should be used. In practice, almost all the tests are done using genetically undefined “albino” rats or mice in which the genetic variation, a major cause of inter-individual and strain variability, is unknown and uncontrolled. This chapter suggests that a better strategy would be to use small numbers of animals of several genetically defined strains of mice or rats instead of the undefined animals used at present. Inbred strains are more stable providing more repeatable data than outbred stocks. Importantly their greater phenotypic uniformity should lead to more powerful and repeatable tests. Any observed strain differences would indicate genetic variation in response to the test substance, providing key data. We suggest that the FDA and other regulators and funding organizations should support research to evaluate this alternative.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Begley CG, Ellis LM (2012) Drug development: raise standards for preclinical cancer research. Nature 483:531–533
Prinz F, Schlange T, Asadullah K (2011) Believe it or not: how much can we rely on published data on potential drug targets? Nat Rev Drug Discov 10:712
Scott S, Kranz JE, Cole J et al (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler 9:4–15
Freedman LP, Cockburn IM, Simcoe TS (2015) The economics of reproducibility in preclinical research. PLoS Biol 13:e1002165
Baker M (2015) Reproducibility crisis: blame it on the antibodies. Nature 521:274–276
Collins FS, Tabak LA (2014) Policy: NIH plans to enhance reproducibility. Nature 505:612–613
Food and Drug Administration (2004) Challenge and opportunity on the critical path to new medical products. [electronic article]. http://www.fda.gov/oc/initiatives/criticalpath/whitepaper html.
Caldwell GW, Ritchie DM, Masucci JA et al (2001) The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery. Curr Top Med Chem 1:353–366
Garner JP (2014) The significance of meaning: why do over 90% of behavioral neuroscience results fail to translate to humans, and what can we do to fix it? ILAR J 55:438–456
Innovative Medicines Initiative (2008) The innovative medicines initiative. http://www.imi.europa.eu/
Russell WMS, Burch RL (1959) The principles of humane experimental technique. Universities Federation for Animal Welfare, Potters Bar, England, Special Edition
Festing MF (2010) Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development. Toxicol Pathol 38:681–690
Festing MFW (1975) A case for using inbred strains of laboratory animals in evaluating the safety of drugs. Food Cosmet Toxicol 13:369–375
Festing MFW (1980) The choice of animals in toxicological screening: inbred strains and the factorial design of experiment. Acta Zool Pathol Antverp 75:117–131
Festing MFW (1986) The case for isogenic strains in toxicological screening. Arch Toxicol Suppl 9:127–137
Festing MFW (1987) Genetic factors in toxicology: implications for toxicological screening. CRC Crit Rev Toxicol 18:1–26
Festing MFW (1990) Contemporary issues in toxicology: use of genetically heterogeneous rats and mice in toxicological research: a personal perspective. Toxicol Appl Pharmacol 102:197–204
Festing MF (2014) Evidence should trump intuition by preferring inbred strains to outbred stocks in preclinical research. ILAR J 55:399–404
Committee on Toxicity (2007) Variability and uncertainty in toxicology of chemicals in food, consumer products and the environment. COT, London, Food Standards Agency
Ashby J, Tinwell H (1994) Use of transgenic mouse lacI/Z mutation assays in genetic toxicology. Mutagenesis 9(3):179–181
Floyd E, Mann P, Long G et al (2002) The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists. Toxicol Pathol 30:147–156
Brown SD, Chambon P, de Angelis MH (2005) EMPReSS: standardized phenotype screens for functional annotation of the mouse genome. Nat Genet 37:1155
Franc BL, Acton PD, Mari C et al (2008) Small-animal SPECT and SPECT/CT: important tools for preclinical investigation. J Nucl Med 49:1651–1663
Petit-Zeman S (2004) Rat genome sequence reignites preclinical model debate. Nat Rev Drug Discov 3:287–288
Chia R, Achilli F, Festing MF et al (2005) The origins and uses of mouse outbred stocks. Nat Genet 37:1181–1186
Yalcin B, Nicod J, Bhomra A et al (2010) Commercially available outbred mice for genome-wide association studies. PLoS Genet 6:e1001085
Aldinger KA, Sokoloff G, Rosenberg DM et al (2009) Genetic variation and population substructure in outbred CD-1 mice: implications for genome-wide association studies. PLoS One 4(3):e4729
Lindsey JR (1979) Historical Foundatins. In: Baker HJ, Lindsey JR, Weisbroth SH (eds) The laboratory rat. Academic, New York, pp 1–36
Festing MFW (1979) Inbred strains in biomedical research. Macmillan Press, London, Basingstoke
Taft RA, Davisson M, Wiles MV (2006) Know thy mouse. Trends Genet 22:649–653
Festing MFW (1976) Phenotypic variability of inbred and outbred mice. Nature 263:230–232
Stevens JC, Banks GT, Festing MF et al (2007) Quiet mutations in inbred strains of mice. Trends Mol Med 13:512–519
Fisher RA (1960) The design of experiments. Hafner Publishing Company, Inc., New York
King-Herbert A, Thayer K (2006) NTP workshop: animal models for the NTP rodent cancer bioassay: stocks and strains--should we switch? Toxicol Pathol 34:802–805
Pritchet K, Clifford CB, Festing MF (2013) The effects of shipping on early pregnancy in laboratory rats. Birth Defects Res B Dev Reprod Toxicol 98:200–205
Keenan KP, Hoe CM, Mixson L et al (2005) Diabesity: a polygenic model of dietary-induced obesity from ad libitum overfeeding of Sprague–Dawley rats and its modulation by moderate and marked dietary restriction. Toxicol Pathol 33:650–674
Richter CA, Birnbaum LS, Farabollini F et al (2007) In vivo effects of bisphenol A in laboratory rodent studies. Reprod Toxicol 24:199–224
Festing MF (2014) Extending the statistical analysis and graphical presentation of toxicity test results using standardized effect sizes. Toxicol Pathol 42:1238–1249
Festing MF (2014) The extended statistical analysis of toxicity tests using standardised effect sizes (SESs): a comparison of nine published papers. PLoS One 9(11):e112955
Festing MFW, Diamanti P, Turton JA (2001) Strain differences in haematological response to chloramphenicol succinate in mice: implications for toxicological research. Food Chem Toxicol 39:375–383
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer Science+Business Media New York
About this protocol
Cite this protocol
Festing, M.F.W. (2016). Genetically Defined Strains in Drug Development and Toxicity Testing. In: Proetzel, G., Wiles, M. (eds) Mouse Models for Drug Discovery. Methods in Molecular Biology, vol 1438. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-3661-8_1
Download citation
DOI: https://doi.org/10.1007/978-1-4939-3661-8_1
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-3659-5
Online ISBN: 978-1-4939-3661-8
eBook Packages: Springer Protocols